Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cancer therapy by biological response modifiers.

R B Herberman

    Clinical Physiology and Biochemistry
    |January 1, 1987
    PubMed
    Summary

    Biological response modifiers (BRMs) enhance the body's immune response against cancer. Research shows their potential in cancer treatment, prevention, and inhibiting metastasis, with genetically engineered cytokines showing promise.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tumor immunology.

    JAMA·1992
    Same author

    The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.

    Cancer research·1992
    Same author

    Receptors for interleukin 2 on human squamous cell carcinoma cell lines and tumor in situ.

    Cancer research·1992
    Same author

    Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role.

    Journal of immunology (Baltimore, Md. : 1950)·1992
    Same author

    Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells.

    International journal of cancer·1992
    Same author

    Tissue distribution of adoptively transferred adherent LAK cells: role of the route of administration.

    Natural immunity·1992

    Area of Science:

    • Oncology
    • Immunology
    • Biotechnology

    Background:

    • Biological response modifiers (BRMs) are investigated for their ability to modulate host responses to tumors.
    • Advances in genetic engineering and monoclonal antibody technology are driving progress in BRM development.
    • Genetically engineered cytokines like interferons and interleukins show promise for cancer therapy.

    Purpose of the Study:

    • To explore the potential of BRMs in cancer treatment and prevention.
    • To understand the mechanisms of BRM antitumor effects for optimal therapeutic protocols.
    • To investigate the role of BRMs in preventing cancer metastasis.

    Main Methods:

    • Review of current research on BRMs, including genetically engineered cytokines.
    • Analysis of animal tumor model systems demonstrating protective effects.
    • Examination of BRMs that stimulate natural killer cell activity.

    Main Results:

    • Genetically engineered cytokines (interferons, interleukins, TNF, CSFs) are advancing to clinical trials.
    • BRMs demonstrate potent protective effects in animal models for cancer prevention.
    • BRMs stimulating natural killer cells show strong protection against tumor cell dissemination.

    Conclusions:

    • BRMs offer a promising avenue for cancer treatment, prevention, and metastasis control.
    • Further research is needed to elucidate mechanisms and optimize clinical application of BRMs.
    • Targeting natural killer cell activity with BRMs is a developing strategy for preventing cancer spread.

    Related Experiment Videos